Po-Shun Lee
Keine laufenden Positionen mehr
Profil
Po-Shun Lee is the founder of Critical Biologics Corp.
which was founded in 2006.
He worked as an Associate Medical Director at Vertex Pharmaceuticals, Inc. from 2010 to 2013.
From 2014 to 2019, he worked as the Chief Medical Officer & Executive Vice President at Proteostasis Therapeutics, Inc. Dr. Lee holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from The Johns Hopkins University.
Ehemalige bekannte Positionen von Po-Shun Lee
| Unternehmen | Position | Ende |
|---|---|---|
| PROTEOSTASIS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 22.07.2019 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.01.2013 |
Critical Biologics Corp.
 Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Founder | - |
Ausbildung von Po-Shun Lee
| University of Pennsylvania | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Critical Biologics Corp.
Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
